Akums Drugs Pharmaceuticals Ltd vs Pharmaids Pharmaceuticals Ltd Stock Comparison
Akums Drugs Pharmaceuticals Ltd vs Pharmaids Pharmaceuticals Ltd Stock Comparison
Last Updated on: May 04, 2026
Key Highlights
The Latest Trading Price of Akums Drugs & Pharmaceuticals Ltd is ₹ 555.5 as of 04 May 10:18
. The P/E Ratio of Akums Drugs & Pharmaceuticals Ltd changed from 21.5 on March 2025 to 0 on March 2021 . This represents a CAGR of -100.00% over 2 yearsThe P/E Ratio of Pharmaids Pharmaceuticals Ltd changed from 89.4 on March 2022 to 0 on March 2021 . This represents a CAGR of -100.00% over 5 years The Market Cap of Akums Drugs & Pharmaceuticals Ltd changed from ₹ 7469 crore on March 2025 to ₹ 0 crore on March 2021 . This represents a CAGR of -100.00% over 2 yearsThe Market Cap of Pharmaids Pharmaceuticals Ltd changed from ₹ 12.9 crore on March 2022 to ₹ 0 crore on March 2021 . This represents a CAGR of -100.00% over 5 years The revenue of Akums Drugs & Pharmaceuticals Ltd for the Dec '25 is ₹ 1193 crore as compare to the Sep '25 revenue of ₹ 1049 crore. This represent the growth of 13.72% The revenue of Pharmaids Pharmaceuticals Ltd for the Dec '25 is ₹ 5.51 crore as compare to the Sep '25 revenue of ₹ 11.63 crore. This represent the decline of -52.62% The ebitda of Akums Drugs & Pharmaceuticals Ltd for the Dec '25 is ₹ 162.96 crore as compare to the Sep '25 ebitda of ₹ 126.84 crore. This represent the growth of 28.48% The ebitda of Pharmaids Pharmaceuticals Ltd for the Dec '25 is ₹ -2.83 crore as compare to the Sep '25 ebitda of ₹ -2.3 crore. This represent the growth of 23.04% The net profit of Akums Drugs & Pharmaceuticals Ltd changed from ₹ 61.21 crore to ₹ 67.67 crore over 7 quarters. This represents a CAGR of 5.90%
The net profit of Pharmaids Pharmaceuticals Ltd changed from ₹ -3.12 crore to ₹ -2.65 crore over 7 quarters. This represents a CAGR of -8.91%
The Dividend Payout of Akums Drugs & Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Pharmaids Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .
About Akums Drugs & Pharmaceuticals Ltd
Akums Drugs and Pharmaceuticals Limited was incorporated vide Certificate of Incorporation dated April 19, 2004 and received a Certificate for Commencement of Business dated May 13, 2004 issued by the RoC.
Alkums Drugs & Pharmas are a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas.
They are into sale of branded pharmaceutical formulations and manufacturing of Active Pharmaceutical Ingredients.
Some of the other services include formulation research and development, preparation and filing of regulatory dossiers into the Indian and global markets, and other testing services.
Some of manufacturing units have been accredited by various global regulatory agencies such as the European Good Manufacturing Practice, the World Health Organization Good Manufacturing Practice and the United States National Sanitation Foundation.
About Pharmaids Pharmaceuticals Ltd
Pharmaids Pharmaceuticals Limited, incorporated in March, 1989 at Hyderabad, Telangana were suppliers of Quality Grade range of speciality chemicals, skin care, hospital care and generic products in the areas of Orthopedic, Neuro and Gastro etc.
The technical team used quality proven chemical compounds and standard processing methods maintaining proper hygiene standards.The Company is engaged in the business of contract research and manufacturing services.
Emergent Bio Naturals Limited (EBNL) was amalgamated with the Company in 2019-20 and the Scheme of Amalgamation was effective on September 27, 2019.
Pursuant to the Scheme, 69,05,734 Equity Shares were allotted to Shareholders of Emergent Bio Naturals Limited on November 27, 2019.
The Company acquired 25.5% stake as 1st tranche in Anugraha Chemicals, a Partnership Firm, registered under Karnataka Partnership Rules, 1954 on February 1, 2023.
FAQs for the comparison of Akums Drugs & Pharmaceuticals Ltd and Pharmaids Pharmaceuticals Ltd
Which company has a larger market capitalization, Akums Drugs & Pharmaceuticals Ltd or Pharmaids Pharmaceuticals Ltd?
Market cap of Akums Drugs & Pharmaceuticals Ltd is 8,615 Cr while Market cap of Pharmaids Pharmaceuticals Ltd is 104 Cr
What are the key factors driving the stock performance of Akums Drugs & Pharmaceuticals Ltd and Pharmaids Pharmaceuticals Ltd?
The stock performance of Akums Drugs & Pharmaceuticals Ltd and Pharmaids Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.
What are the recent stock price for Akums Drugs & Pharmaceuticals Ltd and Pharmaids Pharmaceuticals Ltd?
As of May 4, 2026, the Akums Drugs & Pharmaceuticals Ltd stock price is INR ₹547.4. On the other hand, Pharmaids Pharmaceuticals Ltd stock price is INR ₹29.67.
How do dividend payouts of Akums Drugs & Pharmaceuticals Ltd and Pharmaids Pharmaceuticals Ltd compare?
To compare the dividend payouts of Akums Drugs & Pharmaceuticals Ltd and Pharmaids Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.